Posts Tagged: "Federal Circuit"

SCOTUS Requests Response in CareDx Eligibility Petition Following Michel/ Duffy Brief

Last week, retired U.S. Court of Appeals for the Federal Circuit (CAFC) Chief Judge Paul Michel and law professor John F. Duffy filed an amicus brief with the U.S. Supreme Court in support of CareDx, Inc. and the Board of Trustees of the Leland Stanford Junior University. The company and university are asking the Supreme Court to review a 2022 decision invalidating claims of its patents directed to detection levels of donor cell-free DNA (cfDNA) in the blood of an organ transplant patient. In the amicus brief, Michel and Duffy wrote, “this case concerns [us] because it represents a continuing trend of uncertainty and inconsistency in patent-eligibility jurisprudence…The outcome undermines the innovation promoting goals of U.S. patent law.”

Teleflex Catheter Tech Patents Upheld by Split CAFC

The U.S. Court of Appeals for the Federal Circuit (CAFC) ruled in a precedential decision today that Medtronic, Inc. failed to show the challenged claims of five patents covering catheter technology unpatentable. The CAFC specifically upheld the Patent Trial and Appeal Board’s (PTAB’s) finding that the primary prior art reference cited by Medtronic did not qualify as prior art under pre-America Invents Act (AIA) first-to-invent provisions. Judge Dyk dissented, arguing that the prior art reference had been shown to qualify as prior art, and thus could support a determination of anticipation or obviousness.

CAFC Affirms District Court Denial of Attorney Fees in Oil Drilling Patent Dispute

On Tuesday, the U.S. Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision affirming a district court ruling that denied attorney fees to oil drilling equipment company, FMC Technologies. OneSubsea, a competitor in the offshore oil extraction industry, originally sued FMC for patent infringement in 2015; FMC subsequently countersued. At the heart of the patent infringement dispute was whether fluid flows through FMS’s device, as in the OneSubsea patent.

Reactions to Amgen: Hard Work Ahead for Biotech Innovators and Attorneys Trying to Enable Genus Claims

As most in the IP world know by now, the U.S. Supreme Court issued its ruling in Amgen v. Sanofi on Thursday, holding that the U.S. Court of Appeals for the Federal Circuit (CAFC) was correct in finding that Amgen’s patents for its popular cholesterol drug failed to meet the enablement requirement…. IP practitioners diverge on the degree to which the decision will change patent practice in the biotech industry going forward, with some claiming the Court merely reiterated the existing law on enablement, and others saying it represents a major shift.

Moore Claims She’s Not a Complainant in Latest Special Committee Order on Newman Investigation

The Special Committee of the Judicial Council of the U.S. Court of Appeals for the Federal Circuit (CAFC) that is investigating Judge Pauline Newman over allegations she is unfit to serve on the court issued a redacted order yesterday specifying the behavior they say warrants the probe. Amid calls from Newman’s attorneys and ethics experts to transfer the complaint to a different circuit, a footnote on page one of yesterday’s order somewhat confusingly notes that Chief Judge Moore “did not file a complaint nor is she a complainant. Instead, Chief Judge Moore identified a complaint pursuant to Rule 5, which allows a Chief Judge to initiate the complaint when others have presented allegations establishing probable cause to believe a disability exists.”

Precooked Bacon, Artificial Intelligence Patents, and a Defense of the Common Law

Bacon is delightful. And the similarly savory subject of who must be named inventor on a bacon patent was the issue in the recent case of HIP, Inc. v. Hormel Foods Corp., No. 2022-1696 (Fed. Cir. May 2, 2023). HIP claimed that one of its employees materially contributed to the invention of Hormel’s patent on methods for precooking bacon. The question of what makes one an “inventor” was central to whether HIP’s employee should be added to the patent. More broadly, questions about inventorship and authorship have become central to recent commentary and speculation about the impact of artificial intelligence (AI) on intellectual property law. While AI did not factor into HIP v. Hormel, the decision provides a useful reminder about the role of the common law in developing answers to these momentous questions.

Michel Puts Hope in ‘Imminent’ Patent Bills Following SCOTUS Eligibility Denials

On day one of IPWatchdog’s Patent Litigation Masters program yesterday, the U.S. Supreme Court denied two patent eligibility cases that the U.S. Solicitor General had recommended granting. The denials make it fairly clear that the High Court is not interested in helping to resolve the current problems with U.S. patent eligibility law, which generally have to do with a lack of clarity, arguably fostered by many of the Court’s own precedents. Following the last panel of the day on Monday, in which speakers discussed ways to improve and streamline patent enforcement in America, retired U.S. Court of Appeals for the Federal Circuit Chief Judge Paul Michel told IPWatchdog he thinks the Supreme Court’s refusal to take up patent eligibility is self-serving. “I think the Court doesn’t want to admit they messed up the law in the four decisions – Bilski, Myriad, Mayo and Alice. They don’t even admit that it’s a big problem, but it is a huge problem, and everybody in the patent world knows it’s a huge problem,” Michel said.

‘Obvious Over What?’ LKQ’s En Banc Petition Threatens to Turn Test for Design Patent Obviousness on its Head

Just like utility patents, design patents can be found obvious under 35 U.S.C. § 103 by combining prior art references. But the test for obviousness for design patents differs from the more familiar standards for utility patents. The U.S. Court of Appeals for the Federal Circuit recently reaffirmed this distinction, but the issue is far from resolved. A long line of Patent Trial and Appeal Board (PTAB) actions between LKQ and GM Global Technologies escalated to the Federal Circuit, where LKQ submitted an argument seeking to fundamentally change the obviousness analysis for design patents.

Recapping Eight Years of the Patent Eligibility Mess: Clearly, It’s Past Time for the Supreme Court or Congress to Provide Clarity

Last month, the U.S. Department of Justice filed an amicus brief with the Supreme Court urging the Court to accept a certiorari case relating to patent eligibility. See Interactive Wearables, LLC v. Polar Electro Oy, et al, and David A. Tropp v. Travel Sentry, Inc., Nos. 21-1281 and 22-22. In each of these cases, which were separate from one another, the U.S. Court of Appeals for the Federal Circuit ruled the patents to be ineligible as being abstract ideas, and thus an exception to Section 101 patentable subject matter. This amicus brief follows an earlier amicus brief from the Justice Department, in May 2022, also supporting the petition for certiorari on a patent found by the Federal Circuit to be an abstract idea, and therefore not patentable under Section 101.

Newman Says Moore’s Order Alleging She is Unfit for Court is ‘Riddled with Errors’

U.S. Court of Appeals for the Federal Circuit (CAFC) Judge Pauline Newman yesterday filed a complaint in the United States District Court for the District of Columbia against CAFC Chief Judge Kimberly Moore and Judges Prost and Taranto, as members of the Special Committee of the Judicial Council of the Federal Circuit appointed by Moore to investigate Newman. The complaint called Moore’s March 24 Order characterizing Newman as being unfit to carry out her duties on the court “riddled with errors” and cited 12 counts warranting claims for relief.

CAFC Reverses PTAB Decision that Invalidated Sanofi Injector Pen Patent

The U.S. Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision Tuesday that reversed a Patent Trial and Appeal Board (PTAB) decision invalidating claims of Sanofi’s U.S. Patent No. RE47,614, which covers a drug delivery device. Mylan Pharmaceuticals petitioned the PTAB for inter partes review (IPR) of all 18 claims in Sanofi’s drug injector pen patent. The company argued the patent was invalid due to obviousness, and the PTAB agreed and invalidated the patent. However, Sanofi appealed to the CAFC and argued that Mylan failed to show that the previous patent was analogous to the ‘614 patent. The appeals court agreed with Sanofi because Mylan only argued that two prior patents were analogous and not the challenged patent.

Avery Dennison Urges SCOTUS Review to Prevent Lowered Section 101 Bar from Inflaming ‘Raging Debate’ on Patent Eligibility

On May 8, digital ID solutions company Avery Dennison filed a reply brief with the U.S. Supreme Court in support of its petition for writ of certiorari to appeal the U.S. Court of Appeals for the Federal Circuit’s decision last December affirming the validity of patent claims owned by ADASA. Of the cert petitions currently before the Supreme Court involving issues of patent subject matter eligibility under 35 U.S.C. § 101, Avery Dennison contends that its appeal provides the most useful vehicle for clarifying Section 101 invalidity in information management and technology, a field where the Federal Circuit’s division on patent eligibility “is especially stark and recurrent.”

CAFC Rejects Bid for Attorney Fees in Cannabis Patent Suit

The U.S. Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision Monday affirming a district court’s ruling that denied attorney fees and sanctions to Pure Hemp Collective, Inc. over a patent infringement suit brought against it by United Cannabis Corporation. The patent at issue, U.S. Patent No. 9730911, covers “Cannabis Extracts and Methods of Preparing and Using Same.” United Cannabis sued Pure Hemp for infringement in July 2018, but, following United Cannabis’ bankruptcy proceedings, the parties stipulated to the dismissal of the patent case. United Cannabis’ infringement claims were dismissed with prejudice while Pure Hemp’s invalidity and inequitable conduct counterclaims were dismissed without prejudice.

The Campaign Against Judge Newman Underscores the Downfall of the Federal Circuit

How much damage is Chief Judge Moore doing to the institution that is the Federal Circuit? That question is hard to answer in the present, but there is no doubt that she is causing the type of damage that will linger and perhaps ultimately lead to the downfall of the court itself. Even before the latest episode in which Chief Judge Moore has taken it upon herself to impeach Judge Newman, acting as complainant, investigator, witness and decider, it had become common for many in the industry to ask openly whether the Federal Circuit had outlived its usefulness.

Lock Patent Owner Strikes Out at CAFC in Suit Against Intel

The U.S. Court of Appeals for the Federal Circuit (CAFC) on Friday affirmed a district court’s ruling dismissing antitrust and patent infringement claims brought by a pro se patent owner against Intel. Larry Golden owns a family of patents that cover a system for locking, unlocking or disabling locks on vehicles upon detection of chemical or biological hazards. Golden has also unsuccessfully sued Apple and the U.S. Government for infringement of the patents.